Drug intelligence / Profile preview

Antabio novel target small molecule program

Development stage
Unknown
Lead developer
Antabio
Modality
Small Molecules
01

Overview

Antabio is advancing several discovery-stage programs focused on identifying small molecule inhibitors against novel, undisclosed bacterial targets to combat antimicrobial resistance (AMR). These initiatives include a partnership with the Global Antibiotic Research and Development Partnership (GARDP) to develop new chemical series for high-priority resistant pathogens. By targeting biological pathways distinct from those addressed by current antibiotics, these programs aim to provide new therapeutic options for infections where existing treatments are failing. As these candidates are in the discovery phase, specific chemical structures and precise mechanisms of action remain proprietary.

Other names
Antabio novel target AMR program
02

Targets

MBL (Class B metallo-beta-lactamase)LasB (Pseudomonas aeruginosa elastase)

Beyond the preview

Go deeper on Antabio novel target small molecule program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antabio novel target small molecule program.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call